Wall Street brokerages expect Jaguar Health Inc (NASDAQ:JAGX) to post ($0.25) earnings per share for the current quarter, according to Zacks. Two analysts have issued estimates for Jaguar Health’s earnings. Jaguar Health reported earnings per share of ($42.66) in the same quarter last year, which suggests a positive year over year growth rate of 99.4%. The company is expected to announce its next earnings report on Monday, November 18th.
On average, analysts expect that Jaguar Health will report full year earnings of ($5.31) per share for the current financial year, with EPS estimates ranging from ($5.49) to ($5.12). For the next financial year, analysts expect that the company will post earnings of ($1.30) per share, with EPS estimates ranging from ($2.39) to ($0.70). Zacks’ earnings per share calculations are an average based on a survey of analysts that cover Jaguar Health.
Jaguar Health (NASDAQ:JAGX) last posted its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($9.09) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($5.61) by ($3.48). Jaguar Health had a negative net margin of 727.27% and a negative return on equity of 698.61%. The company had revenue of $1.71 million for the quarter, compared to analyst estimates of $3.05 million.
An institutional investor recently bought a new position in Jaguar Health stock. Wedbush Securities Inc. purchased a new position in shares of Jaguar Health Inc (NASDAQ:JAGX) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 25,100 shares of the biotechnology company’s stock, valued at approximately $33,000. Wedbush Securities Inc. owned 0.05% of Jaguar Health at the end of the most recent quarter. 0.11% of the stock is currently owned by hedge funds and other institutional investors.
Shares of JAGX stock traded down $0.03 during midday trading on Wednesday, reaching $0.74. 286,200 shares of the company traded hands, compared to its average volume of 492,870. Jaguar Health has a 1-year low of $0.64 and a 1-year high of $37.10. The firm’s 50 day simple moving average is $0.91 and its two-hundred day simple moving average is $1.75. The firm has a market cap of $37.09 million, a PE ratio of 0.00 and a beta of 0.71. The company has a debt-to-equity ratio of 0.02, a current ratio of 0.35 and a quick ratio of 0.24.
Jaguar Health Company Profile
Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.
Recommended Story: Street Name
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.